Illumina Inc. Stock
Illumina Inc. Stock
Pros and Cons of Illumina Inc. in the next few years
Pros
Cons
Performance of Illumina Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | -0.200% | -10.000% | -8.406% | -47.323% | -14.693% | -67.071% | -61.429% |
| QuidelOrtho Corp. | -0.550% | -10.448% | -20.160% | -56.385% | -46.918% | -66.512% | - |
| Boston Scientific | 0.000% | -1.550% | 2.651% | 34.963% | 23.445% | 85.999% | 103.460% |
| Waters Corp. | -1.750% | -11.495% | -13.625% | -1.986% | -8.477% | 9.683% | 31.026% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Given a brief glance, Illumina with the US symbol (ILMN) seemingly presents an interesting financial scenario. There exist varied factors in the financials that catch attention, while certain aspects bespeak areas the company needs to address. However, it is important to delve deeper into the data for a comprehensive understanding.
The gross profit as per the Trailing Twelve Months (TTM) indicates a prospect reassuringly. The GrossProfitTTM is 3145000000, referring to overall revenue's percentage that the company retains after direct costs associated with making the products have been considered. Maintaining a healthy gross margin suggests productive internal cost management and pricing policies compared to competitors.
In terms of the company's market appeal indicated by the Price-to-Sales (PriceSalesTTM: 6.6241) and Price-to-Book (PriceBookMRQ: 4.8854) ratios. Both are less than the commonly used threshold of 10 for overvalued prospects, indicating a potentially undervalued situation assuming sustained performance. Thus, for investors keen on value investing, Illumina could be an interesting opportunity.
Comments
News
Why Illumina Stock Zoomed Higher on Thursday
A legal opinion on the other side of Planet Earth put some juice into Illumina's (NASDAQ: ILMN) stock on Thursday. The gene-sequencing specialist saw its share price rise by over 3%, against the S&P
Why Illumina Stock Mashed the Market on Monday
Gene-sequencing stock Illumina (NASDAQ: ILMN) was a standout in the biotech sector Monday, with its share-price rise convincingly beating the S&P 500 index. Investors were cheered by a stock buy
Why Illumina Rallied 36.6% in December
Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.
Investors might not be quite so excited, as Illumina